{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A%3A+pacritinib&page=2", "query": { "intervention": "A: pacritinib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 34, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A%3A+pacritinib&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=A%3A+pacritinib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T08:57:47.173Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05531786", "title": "Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Graft vs Host Disease" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 50, "start_date": "2023-03-06", "completion_date": "2027-07-22", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-04T08:57:47.173Z", "location_count": 2, "location_summary": "Miami, Florida • Bethesda, Maryland", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05531786" }, { "nct_id": "NCT05657613", "title": "Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interactions" ], "interventions": [ { "name": "CYP450 Cocktail and Transporter Substrates with Pacritinib", "type": "DRUG" }, { "name": "Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib", "type": "DRUG" }, { "name": "Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 60, "start_date": "2023-01-03", "completion_date": "2023-06-08", "has_results": false, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-10-04T08:57:47.173Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05657613" }, { "nct_id": "NCT05980806", "title": "A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelofibrosis", "Moderate Thrombocytopenia", "Mild Thrombocytopenia" ], "interventions": [ { "name": "Selinexor 60 mg", "type": "DRUG" }, { "name": "Selinexor 40 mg", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Pacritinib", "type": "DRUG" }, { "name": "Momelotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2024-04-22", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-10-04T08:57:47.173Z", "location_count": 7, "location_summary": "Duarte, California • Columbia, Maryland • New York, New York + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Columbia", "state": "Maryland" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05980806" }, { "nct_id": "NCT01620216", "title": "Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Chronic Myelomonocytic Leukemia", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Antitumor Drug Screening Assay", "type": "OTHER" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pacritinib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Ponatinib", "type": "DRUG" }, { "name": "Ponatinib Hydrochloride", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Sorafenib Tosylate", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2012-05-11", "completion_date": "2017-04-30", "has_results": true, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-04T08:57:47.173Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01620216" }, { "nct_id": "NCT03165734", "title": "A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Myelofibrosis", "Post-polycythemia Vera Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" }, { "name": "Physician's Choice medications", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Swedish Orphan Biovitrum", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 407, "start_date": "2017-06-26", "completion_date": "2028-10-13", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-04T08:57:47.173Z", "location_count": 42, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 29 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03165734" }, { "nct_id": "NCT02532010", "title": "Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia (AML)" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Weill Medical College of Cornell University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 13, "start_date": "2015-06-15", "completion_date": "2017-10-24", "has_results": true, "last_update_posted_date": "2018-06-15", "last_synced_at": "2026-10-04T08:57:47.173Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02532010" }, { "nct_id": "NCT07226713", "title": "Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 32, "start_date": "2026-09-03", "completion_date": "2031-03-01", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-04T08:57:47.173Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07226713" }, { "nct_id": "NCT02323607", "title": "Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Adult Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Therapy-Related Acute Myeloid Leukemia", "Untreated Adult Acute Myeloid Leukemia" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bhavana Bhatnagar", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2016-01-12", "completion_date": "2018-07-12", "has_results": false, "last_update_posted_date": "2019-01-25", "last_synced_at": "2026-10-04T08:57:47.173Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02323607" }, { "nct_id": "NCT02807051", "title": "To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interaction Study" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" }, { "name": "Clarithromycin", "type": "DRUG" }, { "name": "Pacritinib and Clarithromycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 20, "start_date": "2014-09", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2020-01-29", "last_synced_at": "2026-10-04T08:57:47.173Z", "location_count": 1, "location_summary": "Daytona Beach, Florida", "locations": [ { "city": "Daytona Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02807051" }, { "nct_id": "NCT06052618", "title": "Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "KSHV Inflammatory Cytokine Syndrome (KICS)", "Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease" ], "interventions": [ { "name": "Pacritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 75, "start_date": "2025-03-17", "completion_date": "2034-01-01", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-04T08:57:47.173Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06052618" } ] }